Literature DB >> 17708284

A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma.

Wei Lu1, Yan-Hao Li, Zhi-Jian Yu, Xiao-Feng He, Yong Chen, Jian-Bo Zhao, Zhi-Ying Zhu.   

Abstract

BACKGROUND/AIMS: To study liver function damage after transcatheter arterial chemoembolization (TACE) with use of low-dose versus conventional-dose anticancer drugs in patients with hepatocellular carcinoma (HCC).
METHODOLOGY: One hundred and twelve patients with unresectable HCC were randomly divided into two groups to receive superselective TACE. Patients in group A (n=52) received low-dose anticancer drugs: mitomycin C (MMC) 2-8 mg, epirubicin (EPI) 5-10 mg and carboplatin (CBP) 100mg were used. Patients in group B (n=60) were given conventional-dose of anticancer drugs (MMC 10 mg, EPI 40 mg, CBP 300 mg). Lipiodol-anticancer drugs emulsion was injected into the feeding arteries of tumors followed by gelatin sponge (GS) or polyvinyl alcohol (PVA) particles embolization. Liver function was evaluated with Child-Pugh scores, total bilirubin (TBIL), albumin (ALB) and alanine aminotransferase (ALT) before TACE, three days, one week (wk) and four wk after procedures.
RESULTS: In both groups, TBIL, ALT, and Child-Pugh scores increased (P < 0.001 or P < 0.05) and ALB decreased (P < 0.001 or P < 0.01) three days and one wk after TACE. The different between the parameters obtained four wk after the procedure and baseline parameters was not significant in group A (P > 0.05). In group B, however, significant difference (P < 0.05) was found in all parameters except ALT.
CONCLUSIONS: Superselective TACE with use of low-dose anticancer drugs induces transient impairment in liver function, but use of conventional-dose anticancer drugs can cause lasting, more serious worsening of liver function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17708284

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  14 in total

1.  Prognostic factors of spontaneously ruptured hepatocellular carcinoma.

Authors:  Xiang-Jun Han; Hong-Ying Su; Hai-Bo Shao; Ke Xu
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

2.  Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Authors:  Zhu Wang; Hailong Zhang; He Zhao; Xiaoze Wang; Jiaywei Tsauo; Xuefeng Luo; Xiao Li
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

3.  Pathogenic analysis of Vibrio alginolyticus infection in a mouse model.

Authors:  Xiao-Fei Liu; Helin Zhang; Xingshan Liu; Yanwen Gong; Yingjian Chen; Yuan Cao; Chengjin Hu
Journal:  Folia Microbiol (Praha)       Date:  2013-09-25       Impact factor: 2.099

4.  Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?

Authors:  Hiroyuki Kirikoshi; Masato Yoneda; Hironori Mawatari; Koji Fujita; Kento Imajo; Shingo Kato; Kaori Suzuki; Noritoshi Kobayashi; Kensuke Kubota; Shin Maeda; Atsushi Nakajima; Satoru Saito
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

5.  Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

Authors:  Kei Moriya; Tadashi Namisaki; Shinya Sato; Akitoshi Douhara; Masanori Furukawa; Hideto Kawaratani; Kosuke Kaji; Mitsuteru Kitade; Naotaka Shimozato; Yasuhiko Sawada; Kenichiro Seki; Soichiro Saikawa; Hiroaki Takaya; Takemi Akahane; Akira Mitoro; Yasushi Okura; Junichi Yamao; Hitoshi Yoshiji
Journal:  J Gastrointest Oncol       Date:  2018-08

6.  Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors.

Authors:  Zhendong Gao; Gang Du; Yuguang Pang; Zhihao Fu; Chongzhong Liu; Yi Liu; Binghai Zhou; Du Kong; Binyao Shi; Zhengcheng Jiang; Bin Jin
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

7.  An Imaging and Histological Study on Intrahepatic Microvascular Passage of Contrast Materials in Rat Liver.

Authors:  Qian Xia; Yuanbo Feng; Ting Yin; Yewei Liu; Guozhi Zhang; Jianjun Liu; Linjun Tong; Robin Willemyns; Jie Yu; Raymond Oyen; Gang Huang; Yicheng Ni
Journal:  Biomed Res Int       Date:  2017-02-15       Impact factor: 3.411

8.  Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models.

Authors:  Ratna Kumari; Aanchal Sharma; Amrendra Kumar Ajay; Manoj Kumar Bhat
Journal:  Mol Cancer       Date:  2009-10-21       Impact factor: 27.401

9.  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.

Authors:  Hiroki Nishikawa; Yukio Osaki; Ryuichi Kita; Toru Kimura
Journal:  Cancers (Basel)       Date:  2012-02-21       Impact factor: 6.639

10.  Preoperative transcatheter arterial chemotherapy may suppress oxidative stress in hepatocellular carcinoma cells and reduce the risk of short-term relapse.

Authors:  Hao Su; Guangzhi Zhu; Ketut Indra Djaja P; Yi Lin; Yizhen Gong; Xiaoguang Liu; Jiaquan Li; Zhiming Liu; Xiao Qin; Lequn Li; Tangwei Liu; Zili Lu; Minyi Wei; Lunan Yan; Cheryl Ann Winkler; Stephen J O'Brien; Jing Li; Kaiyin Xiao; Tao Peng
Journal:  Oncotarget       Date:  2017-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.